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Summary The effect of the placental hormone chorionic gonadotropin (hCG) on 7,12-dimethylbenz(a)
anthracene (DMBA)-induced mammary tumours was studied in young virgin Sprague-Dawley rats. This
hormone when administered at a dose of 100 IU day-' does not induce toxic effects, measured as alterations in
body weight or weight of endocrine organs, and has a reversible effect on oestrous cycle. The lack of toxicity
and the fact that hCG treatment terminated prior to administration of the chemical carcinogen DMBA
protects the mammary gland from malignant transformation, led us to test the effect of hCG treatment on
DMBA-initiated mammary tumours. Fifty day-old virgin Sprague-Dawley rats received intragastrically 8 mg
DMBA per 100 g body weight and were divided into two groups: group I animals were treated with DMBA
only and group II received DMBA at age 50 and in addition, a daily intraperitoneal injection of 100 IU hCG
for days 21-81 post carcinogen administration. Tumorigenic response was evaluated by biweekly palpation of
all animals and by complete autopsy 24 weeks after DMBA treatment. Group I animals developed an
incidence of 100% of both tumours and adenocarcinomas. Group II animals developed a significantly lower
incidence of tumours and adenocarcinomas, 51.5% and 45.5% respectively. In both groups lesions developed
more frequently in thoracic than in abdominal mammary glands. It is postulated that hCG treatment,
probably through stimulation of ovarian oestrogen and progesterone synthesis, induces differentiation of
mammary epithelium that although affected by the carcinogen can still be rescued from malignant transforma-
tion.
The study of the pathogenesis of 7,12-dimethylbenz(a)an-
thracene (DMBA)-induced rat mammary carcinomas has led
to an understanding of the mechanisms controlling tumour
initiation and of the role played by mammary gland
differentiation (Russo et al., 1977, 1978, 1979, 1980, 1987a).
The mammary gland of Sprague-Dawley rats exhibits the
highest susceptibility to malignant transformation when the
carcinogen affects undifferentiated terminal ductal structures
or terminal end buds (TEBs) which are present in the
immature gland of young virgin animals (Russo et al., 1977,
1987a). The susceptibility of the mammary gland to neoplas-
tic transformation decreases progressively with ageing and
more markedly with differentiation, such as that occurring
after full-term pregnancy (Dao et al., 1960; Grubbs et al.,
1983a, 1986; Moore et al., 1981; Russo et al., 1978, 1979,
1980, 1987a). An additional factor influencing the suscep-
tibility of the mammary gland to carcinogenesis is the asyn-
chronous development of mammary glands located in
different topographic locations. Mammary glands located in
the thoracic region develop a greater number of tumours
than those located in the abdominal or inguinal regions
(Gullino et al., 1975; Moore et al., 1981; Russo et al., 1987a),
what is attributed to a delayed differentiation of thoracic
mammary glands (Russo et al., 1987a).
Although it is known that both mammary differentiation
and tumorigenesis are modulated by hormones, and that a
majority of chemically-induced mammary cancers are hor-
mone dependent, since they can be suppressed by either
hormone deprivation, hormone administration, or by preg-
nancy and lactation (Dao et al., 1960; Grubbs et al., 1983a,
b, 1986; Huggins et al., 1961; McCormick et al., 1973; Moore
et al., 1981; Nicholson et al., 1988; Russo & Russo, 1986,
1988; Welsch, 1985), the definitive role of hormones in
tumour progression still remains to be elucidated. The res-
ponse of the mammary gland affected by a carcinogen to
hormone administration is greatly influenced by the type and
dose of hormone administered, as well as by the sequence in
which either hormones or carcinogens reach the mammary
epithelium. The hormones produced by a full term pregnancy
terminated prior to carcinogen administration protects the
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mammary gland from neoplastic transformation (Dao et al.,
1960; Russo et al., 1980, 1987a), whereas pregnancy initiated
after carcinogen administration has been reported to shorten
the latency period, to accelerate the growth of mammary
cancer and to increase the number of active centres (Huggins
et al., 1962). Dao et al. (1960) also reported shortened
latency period in tumour development during pregnancy and
increased short term tumour incidence, but decreased overall
tumorigenic response, whereas Moore et al. (1981) and
Grubbs et al. (1986) found pregnancy to be protective.
It has been shown that the protective effect of pregnancy
prior to carcinogen administration is due to induction of
differentiation of the mammary gland (Russo et al., 1978,
1980), however, the exact mechanism of action of each
specific hormone prior to or after carcinogen administration
is not known. It has not been clarified what hormonal levels
or what hormone combinations determine the protective
degree of gland development induced by pregnancy. Al-
though most attempts to stimulate mammary development
have utilised ovarian hormones, pituitary hormones, or syn-
thetic agents (Dao et al., 1960; Huggins et al., 1962; McCor-
mick et al., 1973; Welsch, 1985) the role of the most abun-
dant placental hormone, chorionic gonadotropin, on mam-
mary gland differentiation has not been explored. Chorionic
gonadotropin, a polypeptide hormone produced by the pla-
centa is composed of an alpha and a beta subunit. The alpha
subunit is identical to that of the pituitary gonadotropins
luteinizing hormone (LH), follicle stimulating hormone
(FSH) and thyroid stimulating hormone (TSH). The beta
subunits of these hormones differ in amino acid sequence
(Segal, 1980). The action of chorionic gonadotropin is iden-
tical to that of LH and has some small degree of FSH
activity, stimulating production ofprogesterone by the ovary.
We have determined that treatment of intact virgin rats
with chorionic gonadotropin affects the mammary gland
structure, cell kinetics and level of cell differentiation (Russo,
1983). HCG mimics the physiological effect of pregnancy,
since treatment of virgin rats with 10-1OOIU for 21 days
prevents the initiation of mammary cancer through induction
of long-lasting structural changes in the mammary gland,
namely a greater lobular formation, with concomitant reduc-
tion in the number of TEBs and in the rate of cell prolifera-
tion of the mammary epithelium (Russo, 1983).
These data indicate that mammary gland differentiation
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prior to exposure to a carcinogen by means other than
pregnancy is a reasonable approach for mammary cancer
prevention (Russo et al., 1987a, 1988; Russo, 1983; Tay et
al., 1985). In devising strategies for hormone prevention of
mammary carcinogenesis in the human population, however,
it is important to bear in mind an important difference
between the human and the experimental conditions; in ex-
perimental animals the time and site of appearance of mam-
mary lesions have been identified (Russo et al., 1977) whereas
in the human population the site of origin has been pos-
tulated (Russo et al., 1987b, 1990), but the time of initiation
of neoplasms is not known. Since it is not known whether,
and if so when, the breast of human females has been
exposed to possible carcinogenic stimuli, it is necessary to
assume that the entire population is at risk, and as a conse-
quence, it is important to determine what effect hCG would
have when administered after exposure of a gland to a
carcinogen. Based upon this rationale, we have treated ani-
mals already exposed to DMBA with the same dose of hCG
shown to be protective when administered prior to car-
cinogen exposure (Russo et al., 1987a).
Materials and methods
Animals
All the experiments were carried out using virgin Sprague-
Dawley rats that were originally purchased from Harlan
Sprague-Dawley, Indianapolis, IN. The animals were main-
tained at a temperature of 24 ± 1°C with controlled lighting
(12 hrs light: 12 hrs darkness). They received water and food
ad libitum.
Experimentalprotocol
In order to determine whether hCG treatment has a toxic
effect on Sprague-Dawley rats, 50 day-old virgin rats were
inoculated daily with an intraperitoneal (i.p.) injection of
100 IU hCG (Sigma Chemical Company, St Louis, MO);
age-matched animals were used as controls. One group of
treated and another of control animals were sacrificed on the
first day of injection, another two groups at the end of the
21st injection and 21 days after termination of the injections.
A daily vaginal smear was obtained from treated and control
animals. At the time of sacrifice the weights of the body and
of the pituitary gland, adrenals, ovaries and uterus were
determined. The internal organs were fixed in 10% neutral
buffered formalin and processed for light microscopy.
In order to assess the role of hCG on the progression of
DMBA mammary carcinomas, fifty day-old virgin rats were
divided into two groups: group I animals received a single
intragastric dose of 8 mg DMBA per 100 g body weight
(Eastman Organic Chemicals, Rochester, NY). DMBA was
dissolved in corn oil heated in a water bath at 100°C for
15 min. After carcinogen administration, the animals re-
mained undisturbed, except for bi-weekly palpation for detec-
tion of tumour development. Group II animals were admin-
istered DMBA at age 50, as group I animals, but starting 21
days after carcinogen administration, time at which intraduc-
tal proliferations have been reported to be already present
(Russo et al., 1977), they received one daily intraperitoneal
(i.p.) injection of 100 IU chorionic gonadotropin (hCG) (Sig-
ma Chemical Company, St Louis, MO) for 60 days. All the
animals were weighed at the beginning of the experiment,
and at 16 weeks post-treatment. Weights determined at the
end of the experiment were not utilised to avoid the influence
of tumour burden, mainly in group I animals. All the
animals were palpated twice a week for detection of tumour
development. Date of tumour appearance, tumour location
and tumour size, which was measured in two dimensions
with a vernier caliper, were recorded. All the animals were
killed 24 weeks post-DMBA administration. All tumours and
the mammary glands were dissected from the skin and pro-
cessed as described elsewhere (Russo et al., 1989a). Sections
of tumours were stained with hematoxylin and eosin and
tumours were classified by applying criteria published else-
where (Russo et al., 1989b,c).
In addition to classifying the tumours by their histological
type, they were also tabulated according to their site oforigin
in either the thoracic or the abdominal regions. Tumours in
the thoracic region included all tumours which developed
within the 1st, 2nd and 3rd mammary glands of the right and
left sides. Tumours in the abdominal region were those
developed in the 4th, 5th and 6th right and left mammary
glands.
Statistical analysis
Body weights and the weight of endocrine organs and the
proportions of DMBA-induced tumours and DMBA-induced
adenocarcinomas were analysed using Fisher's exact test
(Zar, 1984).
Results
Effect ofhCG treatment on body weight, oestrous cycle and
endocrine organs
Both control and experimental animals had similar body
weights at the beginning of treatment. Body weight increased
naturally with age, and the gain in weight was linear in both
control and treated animals (Table I), indicating that hCG
treatment did not exert a toxic effect and did not affect food
intake or food utilisation in treated animals.
HCG treatment modified the oestrous cycle in approx-
imately 40% of the animals which went into dioestrus by the
third day ofinjection. Dioestrus was maintained until the last
day of injection. The treatment did not modify significantly
the oestrous cycle in approximately 60% of the animals,
which continued cycling, although there was a tendency to
induce prolongation of dioestrus. One to two days after the
last hCG injection most of the animals went into proestrus
and then oestrus, which in 50% of the animals persisted for
the first 8 days post-injection; In the remaining animals cycles
returned to normal. Between the 8th and 21st days post-
injection all the animals were cycling although with a
tendency to exhibit prolongation of oestrus.
Treated animals did not exhibit significant differences in
pituitary and adrenal gland weights in comparison with con-
trols (Table I). No histological abnormalities were noted in
these organs as a consequence of treatment. HCG treatment
induced a significant increase (P<0.01) in ovarian weight
over the weight of controls. The maximal increase occurred
at the end of treatment, decreasing thereafter; although the
ovarian weight of treated animals remained at a higher value
than in virgin controls, the difference was not significant. The
increase in weight was due to an increase in number and size
of corpora lutea, which were histologically normal. No
significant differences in uterine weight were observed
between treated and virgin control animals (Table I).
Effect ofhCG on DMBA-induced mammary carcinogenesis
All group I animals developed mammary tumours (Table II,
Figure 1), a total of 121 tumours, 60.3% located in the
thoracic region and 39.7% in the abdominal region (Tables
III and IV). The tumours were multiple, with an average of
4.0 tumours per animal (Table II and Figure 2).
Treatment with the placental hormone hCG significantly
decreased the incidence of DMBA-induced mammary tu-
mours, since experimental or group II animals, which had
not developed palpable tumours at the time of initiation of
hCG injection, exhibited a markedly reduced tumour inci-
dence at the end of the observation period (Table II, Figure
1). Only 17 animals (51.5%) developed a total of 31 tumours
by 24 weeks post carcinogen administration (Table II, Figure
1). Of the 31 tumours developed, 21 (67.7%) were located in
the thoracic region and 10 (32.3%) in the abdominal regionPROTECTIVE EFFECT OF CHORIONIC GONADOTROPIN 245
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Figure 1 Effect of hCG treatment on the time of appearance of
palpable mammary tumours. Rats received DMBA at 50 days of
age; 100 IU hCG were injected daily for weeks 3 to 13 post-
carcinogen administration.
Figure 2 Effect of treatment on the frequency distribution of
mammary tumours. Number of animals, ordinate; number of
tumours per animal, abscissa.
Table I Influence of hCG treatment on body and endocrine organ weight
Weight 21 days after
Weight at end of termination of
hCG treatment hCG treatment
Parameter Initial weight Control Treated Control Treated
Body weighta 158.0 ± 8.4 223.5 ± 8.2a 213.0 ± 6.7b 266.5 ± 20.0c 237.1 ± 22.2d
Pituitaryb 9.7 3.7 11.5± 2.5a 13.7± 1.1b 15.5± 1.9c 16.9± 2.9d
Adrenalsb 81.4 ± 11.8 78.2 ± 8.6a 72.4 ± 7.6b 82.6 ± 12.6c 62.6 ± 26.7d
Ovariesb 107.4 30.3 130.8 20.4e 240.0 ± 56.3f 109.9± 17.79 150.0 32.6h
Uterusb 412.6 83.9 459.4 124.9a 410.0 ± 107.9b 531.2 98.0c 435.3 ± 61.7d
Analysis of variance showed no significant differences in weight between a,b,c and d. Significant differences were e vs f (P<0.01) and f vs h
(P<0.01); g vs h was not significant.
0Bodyweight in grams, mean+s.d. bEndocrine organ weight in mg, mean±s.d.
Table II Effect of hCG treatment after DMBA administration on tumour progression
An. with
Body weight' An. with tumours adenocarcinomas
Total no. Total no. Latency period
No. at at No. No.
Group Treatment an. 50 days 134 days No. % tumours TIANb No. % AdCa' AdCaIANd in days
I DMBA' 30 159.7± 7.1 244.2± 15.8 30 100g 121 4.0 30 10"h 93 3.1 49-154
II DMBAe
+hCGf 33 153.2± 10.0 250.0± 10.2 17 51.5g 31 0.9 15 45.5h 26 0.8 49-154
aBodyweightingrams, mean ± s.d.,determined atages 50and 134daysofage. Theweight wasdetermined 12weekspost-DMBA administration
in order to avoid the large dispersion due to tumour burden occurring by the end of the experiment. "Number of tumours per animal per total
number of animals at risk. cAdCa, adenocarcinoma. dNumber of adenocarcinomas per animal per total number of animals at risk. CDMBA,
7,12-dimethylbenz(a)anthracene, 8 mgper 100 gbodyweight.`hCG, humanchorionicgonadotropin, 100 IUday-' for 60days. gTumour incidence
in group I vsgroup II is highly significant(Fisher's exact testtwo-tail, P = 3.18 x 10-6). hAdenocarcinoma incidence in group I vsgroup II ishighly
significant (Fisher's exact test two-tail, P = 4.34 x 10-7).
Table III Topographic distribution of DMBA-induced mammary tumours
Animals with tumours
Thoracic +
Thoracic MG' Abdominal MGb Abdominal MGC
Group Treatment No. an. No. % No. % No. %
I DMBA 30 7 23.3 0 0 23 76.6
II DMBA + hCG 33 8 24.2 5 15.5 4 12.1
0Animals with tumoursin thoracicmammaryglandsonly."Animalswith tumours inabdominalmammaryglandsonly.cAnimalswith tumoursin
both thoracic and abdominal mammary glands.
Table IV Topographic distribution of DMBA-induced benign and malignant mammary tumours
Tumour distribution
Tumours Thoracic MG Abdominal MG
AdCAc Fibroadd Tumours Fibroad AdCA Tumours Fibroad AdCA
No. Total
Group Treatment an no. No. % No. % No. % No. % No. % No. % No. % No. %
I DMBAa 30 121 93 76.8 28 23.2 73 60.3 13 10.7 60 49.6 48 39.7 15 12.4 33 27.3
II DMBA
+ hCGb 33 31 26 83.9 5 16.1 21 67.7 2 6.4 19 61.3 10 32.3 3 9.6 7 22.6
aDMBA, 7,12-dimethylbenz(a)anthracene, 8 mg 100 g- 'bodyweight. bhCG, human chorionic gonadotropin, 100 IUday' for 60days.cAdCa,
adenocarcinoma. dFibroad, Fibroadenoma.
100-1
. 80
I.0
:3 0
E 60
§ 40
*E 20
0
+
-I-
0
IRW IRWIRWIRWlw246 I.H. RUSSO et al.
(Table IV). The number of tumours per animal was markedly
reduced, since the average number of tumours per animal per
number of animals with tumours was 1.8 and the number of
tumours per animal per number of animals at risk was 0.9
(Table II). Tumours became palpable as early as 49 days
post-carcinogen administration in both groups. The time of
tumour appearance ranged from 49 to 154 days, with no
statistical differences between control and experimental
groups (Table II). Many tumours were not palpable and were
first detected at the time of autopsy.
When the tumours were histologically classified, it was
found that in group I animals, 93 out of 121 tumours
(76.8%) were adenocarcinomas (Table IV); they developed in
100% of the animals, with an average of 3.1 adenocar-
cinomas per animal (Table II); 64.5% of adenocarcinomas
were located in the thoracic region and 35.5% in the ab-
dominal region. Adenocarcinoma incidence was markedly
reduced in group II animals. Of a total of 31 tumours
developed 26 were adenocarcinomas, which were present in
only 45.5% of the animals (Table II). The number of car-
cinomas per animal was reduced to 1.7 adenocarcinomas per
animal per number of animals with tumours, or 0.8 tumours
per animal per number of animals at risk (Table II); 73% of
the adenocarcinomas were located in the thoracic region, and
27% in the abdominal region. The incidence of adenocar-
cinomas in group II was significantly lower than in group I
animals (Table II). Although the percentage of adenocar-
cinomas was substantially higher in thoracic than in
abdominal mammary glands, tumour distribution was similar
in groups I and II animals, as shown by the x2 test. Benign
lesions, which consisted exclusively of fibroadenomas,
represented 23.2% and 16.1% of the total number of lesions
in groups I and II animals respectively. Their distribution did
not differ significantly between the two topographic regions
(Table IV).
Discussion
Results presented here demonstrate that human chorionic
gonadotropin (hCG) treatment of virgin Sprague-Dawley rats
in which mammary carcinomas have been initiated by
administration of DMBA are significantly protected from
tumour development.
The choice of hCG treatment was based upon the observa-
tion that full-term pregnancy-induced gland differentiation
occurring before carcinogen administration is a protective
factor in chemically induced mammary gland carcinogenesis
(Russo, 1983; Russo et al., 1978, 1980, 1987a); this observa-
tion suggested to us that placental hormones play an impor-
tant role in both mammary development and protection from
neoplastic transformation.
Chorionic gonadotropin (CG) produced by the placenta of
rats, mice and hamsters is structurally similar to human CG
(Wide et al., 1980). In rodents, significant amounts of CG
have been detected in extracts of implantation sites of placen-
tae throughout the period of gestation, with a maximum level
detected between days 11 and 13 (Wide et al., 1980).
The protective effect of hCG on mammary carcinogenesis
was first reported in 1983 (Russo, 1983). Doses of 10 or.
100 IU applied daily for 21 days were found to be protective
even when treatment was terminated 21 days prior to car-
cinogen exposure (Russo, 1983; Russo et al., 1987a). HCG
administered at these doses is not tumorigenic per se and
does not induce alterations in body weight or in the weight
of endocrine organs such as pituitary gland, ovaries and
adrenal gland. It induces alterations in the oestrous cycle
during the time of administration, but this effect reverts upon
discontinuation of hormone administration.
Results reported here demonstrate that pharmacological
doses of hCG administered 21 days after the carcinogen
produce significant reduction in the number of tumours and
of adenocarcinomas developed, even though tumour initia-
tion has already taken place (Russo et al., 1977). Tumour
development was constantly depressed throughout the injec-
tion period and thereafter, what indicates that the inhibitory
effect of the hormone is persistent and probably due to
structural alterations of the mammary gland. The observa-
tion that thoracic mammary glands retain their greater sus-
ceptibility to neoplastic transformation even after the hor-
monal treatment indicates that hCG affects equally mam-
mary glands located in different topographic areas without
altering intrinsic properties of the mammary epithelium in-
volved in this process.
The comparison of the effect of hCG treatment with that
of pregnancy is straightforward with results reported by
Grubbs et al. (1983a, 1986) and Moore et al. (1981), who
found a protective effect when pregnancy was initiated soon
after carcinogen administration. Dao et al. (1960) also re-
ported complete inhibition of tumorigenesis when pregnancy
was initiated simultaneously with carcinogen administration,
and reduced overall tumour incidence when pregnancy was
initiated at a later date, although these authors report de-
creased latency period and greater short term tumour inci-
dence. Huggins et al. (1962), on the other hand, reported
shortened latency period and greater overall tumour inci-
dence when pregnancy was initiated 15 days post-DMBA
administration. The period of time between carcinogen ad-
ministration and hormonal stimulation seems to be the most
crucial event in determining the final tumorigenic response;
10 days post MNU administration (Grubbs et al., 1986) or 6
days after DMBA administration reduces considerably
tumour incidence, but no reduction occurs when mating is
delayed 3 weeks (Moore et al., 1981). In 3-MC treated rats
the reduction is not so dramatic when mating occurs between
5 and 10 days post-carcinogen administration (Dao et al.,
1960). We still find protection when hCG is administered 21
days post-carcinogen treatment. These findings support the
hypothesis that a placental hormone is able to modulate the
initiated cell, thus blocking the progression of the neoplastic
process.
The protective effect of hCG treatment prior to carcinogen
administration is mediated through induction of gland
differentiation, reduction in the proliferative activity of the
mammary epithelium, reduction in binding of carcinogen to
DNA and increasing DNA repair capabilities of the mam-
mary epithelium (Russo, 1983; Russo et al., 1987a; Tay et al.,
1985). When given to young virgin rats, DMBA affects the
highly proliferating epithelium of terminal end buds (TEBs).
Cells affected by the carcinogen become transformed, devel-
oping intraductal proliferations (IDPs); by 21 days post-
carcinogen administration, time at which hCG treatment was
started, only a small number of IDPs had developed (Russo
et al., 1977, 1982). It remains to be clarified whether HCG
administration acts by inhibiting cell proliferation and induc-
ing differentiation in IDPs already present, as well as in those
TEBs not expressing transformation yet. Although there is
scanty information on the direct effect of hCG on the mam-
mary gland, in vitro data indicate that hCG inhibits pro-
liferative activity of the mammary epithelium (Moviglia et
al., 1984; Russo et al., 1985). Although hCG has been
associated with tumorigenesis, since it is secreted by num-
erous trophoblastic and non-trophoblastic neoplasms (Asa et
al., 1984; Chou et al., 1978), it is not known at the present
time what is the mechanism whereby hCG significantly
decreases overall tumour incidence and tumour burden. Its
effect has been reported variously to be that of an immuno-
suppressive agent (Contractor et al., 1973), a mitogenic
agent, a local growth factor (Melmed et al., 1983), or an
activator of c-myc and c-fos oncogenes, which in turn are
important in the regulation of cell differentiation and pro-
liferation (Cochran et al., 1984; Czerwiec et al., 1989). Exo-
genous administration of hCG affects multiple endocrine
organs; when given to rats in dioestrus it increases the plasma
concentration of pituitary follicle-stimulating and luteinising
hormones prior to induction of premature ovulation (Kimura
et al., 1983; Segal, 1980; Uilenbrock et al., 1985). It increases
oestradiol concentrations in immature female rats which is
associated with increased aromatase activity and is preceded
by decreased 5-alpha-reductase activity (Uilenbrock et al.,PROTECTIVE EFFECT OF CHORIONIC GONADOTROPIN 247
1985). Therefore, it is possible to postulate that the main
effect of hCG on the mammary gland is mediated through
stimulation of production of ovarian oestrogens and pro-
gesterone which in turn play an important role in tumour
growth (Dao et al., 1959, 1960; Grubbs et al., 1983b, 1986;
Huggins et al., 1961, 1962; McCormick et al., 1965, 1973;
Welsch, 1985).
Even though the mechanism of action of hCG remains to
be explored, our results indicate that hCG in adequate
doses may be a suitable hormone in breast cancer prevention
and tumour progression after carcinogenic initiation. This
knowledge eliminates the uncertainty of whether hCG treat-
ment stimulates a process that had been already initiated at
the time of hormonal treatment.
This study was supported by American Cancer Society Grant Num-
ber BC-621 and an Institutional Grant from the United Foundation
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